117 related articles for article (PubMed ID: 17982058)
1. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
Otahal P; Knowles BB; Tevethia SS; Schell TD
J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
[TBL] [Abstract][Full Text] [Related]
2. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
4. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
[TBL] [Abstract][Full Text] [Related]
6. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
7. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.
Yorty JL; Tevethia SS; Schell TD
Cancer Immunol Immunother; 2008 Jun; 57(6):883-95. PubMed ID: 18004562
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.
Mylin LM; Schell TD; Roberts D; Epler M; Boesteanu A; Collins EJ; Frelinger JA; Joyce S; Tevethia SS
J Virol; 2000 Aug; 74(15):6922-34. PubMed ID: 10888631
[TBL] [Abstract][Full Text] [Related]
9. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.
Schell TD
J Virol; 2004 Feb; 78(4):1751-62. PubMed ID: 14747540
[TBL] [Abstract][Full Text] [Related]
10. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
11. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice.
Ye X; McCarrick J; Jewett L; Knowles BB
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3916-20. PubMed ID: 8171012
[TBL] [Abstract][Full Text] [Related]
12. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.
Ryan CM; Staveley-O'Carroll K; Schell TD
J Immunother; 2008; 31(9):906-20. PubMed ID: 18832997
[TBL] [Abstract][Full Text] [Related]
13. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL.
Lyman MA; Aung S; Biggs JA; Sherman LA
J Immunol; 2004 Jun; 172(11):6558-67. PubMed ID: 15153470
[TBL] [Abstract][Full Text] [Related]
14. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
[TBL] [Abstract][Full Text] [Related]
15. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
Ward-Kavanagh LK; Kokolus KM; Cooper TK; Lukacher AE; Schell TD
Cancer Immunol Immunother; 2018 Apr; 67(4):639-652. PubMed ID: 29332158
[TBL] [Abstract][Full Text] [Related]
16. Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.
Romieu R; Baratin M; Kayibanda M; Lacabanne V; Ziol M; Guillet JG; Viguier M
J Immunol; 1998 Nov; 161(10):5133-7. PubMed ID: 9820481
[TBL] [Abstract][Full Text] [Related]
17. An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses.
Bruns M; Wanger J; Utermöhlen O; Deppert W
Oncotarget; 2015 Nov; 6(36):38487-503. PubMed ID: 26513294
[TBL] [Abstract][Full Text] [Related]
18. Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen.
Soldevila G; Geiger T; Flavell RA
J Immunol; 1995 Dec; 155(12):5590-600. PubMed ID: 7499842
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells.
Wong SB; Bos R; Sherman LA
J Immunol; 2008 Mar; 180(5):3122-31. PubMed ID: 18292535
[TBL] [Abstract][Full Text] [Related]
20. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.
Cozza EM; Cooper TK; Budgeon LR; Christensen ND; Schell TD
Cancer Immunol Immunother; 2015 Mar; 64(3):325-36. PubMed ID: 25408469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
